The general agency brand promotion business (CSO) continued to advance an integrated "product-brand-marketing" approach, actively building a full-value-chain marketing and promotion system, and has established itself as a leading enterprise in the out-of-hospital pharmaceutical CSO sector. While core agency products continued to drive growth, the introduction and cultivation of new products yielded tangible results, the product mix was further optimized, and brand management as well as marketing and promotional capabilities were continuously enhanced.

In terms of product variety expansion for the pharmaceutical CSO business, the Company has secured agency rights for well-known products from numerous top-tier manufacturers in the industry, including Kewei, KangWang, Beiping, Methycobal, Merislon, and Kenvue, with a cumulative total of over 817 agency product specifications. Among these, 32 star products each achieved annual sales exceeding 100 million. In 2025, the Company introduced 113 new products, of which 20 exceeded 10 million in sales, covering full varieties across chronic diseases, oncology, anti-infectives, and other categories, and spanning full channels in the comprehensive health retail sector. Since 2025, the Company has entered into strategic cooperation agreements with well-known brands including LEO Pharma China, Hisun Pharmaceutical, and Haleon, securing agency rights across full retail channels for 8 product specifications under LEO Pharma China's Calcipotriol series and 3 products from Hisun Pharmaceutical including Methylprednisolone Tablets (Medrol), while also taking on the promotion and service of Haleon's star products across broad medical channels, including Caltrate, Centrum, Voltaren, Baiduobang, and Contac.

In terms of product variety expansion for the medical device CSO business, the Company has secured agency rights for 1,612 product specifications, covering 15 product lines from 11 major manufacturers, with 20 product specifications each achieving annual sales exceeding 100 million. Meanwhile, the Company actively cultivated high-potential new product varieties, introducing cardiac valve, reagent, and dental product lines in 2025, providing new growth momentum for the medical device general agency business.